Definium's DT120 Shows Rapid, Durable Efficacy in Phase 3 Depression Trial
Event summary
- Definium's DT120 ODT met primary endpoint in Phase 3 Emerge study for major depressive disorder (MDD), showing statistically significant improvement over placebo.
- Single dose of DT120 produced rapid response (-14.2 LS mean reduction in MADRS at Week 1) and durable effects (-7.3 LS mean reduction at Week 12).
- DT120 was well-tolerated with 99% of adverse events mild to moderate, no new safety signals identified.
- Study enrolled 149 participants across 20 sites, with 35% response rate (≥50% MADRS reduction) vs. 7% for placebo.
The big picture
Definium's positive Phase 3 results position DT120 as a potential game-changer in depression treatment, addressing critical unmet needs around rapid onset and durable response. The data suggests psychedelic-assisted therapies could disrupt the $326 billion annual economic burden of MDD in the U.S., though commercialization will require navigating regulatory hurdles unique to this emerging therapeutic class.
What we're watching
- Regulatory Pathway
- Whether the FDA will accept these results as sufficient for approval given DT120's novel mechanism.
- Market Differentiation
- How Definium positions DT120 against existing antidepressants and other psychedelic therapies in development.
- Clinical Validation
- The pace at which additional Phase 3 data (Ascend study) confirms these findings across different MDD patient populations.